HOME >> MEDICINE >> NEWS
JCI table of contents: January 19, 2006

EDITOR'S PICK
Vitamin D signals to prevent bone loss during osteoporosis

The risk of bone fracture resulting from falls increases as we age due to bone loss and osteoporosis. Physicians have routinely prescribed vitamin D and vitamin Drelated drugs to retard bone loss, but until now, little was known about the specific targets of vitamin D in bone. In a study appearing online on January 19 in advance of print publication in the February 2006 issue of the Journal of Clinical Investigation, Kyoji Ikeda and colleagues from the National Center for Geriatrics and Gerontology in Japan examine mice with severe osteoporosis and show that oral vitamin D treatment inhibits the production of the protein c-Fos. As c-Fos plays a key role in the development of osteoclasts, which are the specialized cells responsible for bone breakdown and resorption, the authors also show that the vitamin Dmediated inhibition of c-Fos prevented bone loss through a suppression of osteoclast development. In addition, the authors used mice whose ovaries had been removed, in a more "human-like" model of osteoporosis, to screen for other vitamin Dlike agents with c-Fossuppressing activity. They identified a new vitamin Drelated compound (DD281) that could prevent bone loss in these mice more potently than the natural vitamin D. These findings clarify how vitamin D helps limit bone resorption in conditions such as osteoporosis, and suggest that synthetic vitamin D analogs, including DD281, may warrant clinical trial to asses their potential in the treatment of osteoporosis and other related disorders of bone resorption.

TITLE: c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs

AUTHOR CONTACT:
Kyoji Ikeda
National Center for Geriatrics and Gerontology, Obu, Japan
Phone: 81-562-46-8094; Fax: 81-562-46-8094; E-mail: kikeda@nils.go.jp

View the P
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
19-Jan-2006


Page: 1 2 3 4 5 6

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents January

(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
Cached News: